News

The 23rd Parkinson’s Unity Walk will take place on April 22 in New York City’s Central Park, according to The Parkinson Alliance. The walk is the largest grassroots fundraiser for Parkinson’s disease research in the U.S. Thousands of patients, caregivers, family, and friends will gather for the walk (or participate from home) to raise money for the…

Parkinson’s disease patients are known to be at a higher risk of falling, due to the changes in the brain caused by the disease. Recently, a study found that exercise may help prevent these falls. Researchers found that 25% of recently-diagnosed Parkinson’s patients suffer a fall in their first…

Folinic acid, an adjuvant medication for bowel cancer, also may become a potential treatment for early-onset Parkinson’s disease, according to results of a preclinical study that used fruit flies. The study “Folinic Acid Is Neuroprotective In A Fly Model Of Parkinson’s Disease Associated With pink1 Mutations” was published in…

3-D images of 11 mutant versions of a protein connected with Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are helping scientists understand how the mutations changed the structure of the protein and damaged its functioning. The study, “Structural insights into human angiogenin (ANG) variants implicated in Parkinson’s disease…

Long forgotten by his own country, 18th-century English-born physician James Parkinson was honored at a global conference March 10-11 to mark two centuries of progress in understanding the disease that today bears his name. Organized by the International Parkinson and Movement Disease Society (MDS), the event paid homage to…

Partners in Parkinson’s has opened a video gallery online to help educate people about the disease and to support services to Parkinson’s patients worldwide. The group is also planning to host information events in two U.S. cities this year. The gallery’s aim is to bring essential information to patients that can…

A sublingual spray of apomorphine shows promising results in a Phase 1 pilot study for the treatment of severe uncontrollable motor fluctuations in late-stage Parkinson’s disease (PD) patients, the British specialty drugmaker Renown Pharma has announced. Apomorphine is currently the only drug approved specifically to treat “off” episodes in patients with…

Researchers at two world-renowned institutions have presented a new theory of how Parkinson’s disease (PD) and its symptoms develop— challenging the dominant view that PD emerges as the protein alpha-synuclein spreads from neuron to neuron in an infection-like manner. In an opinion piece, “The Threshold Theory for Parkinson’s Disease,” the two…

The MC1R gene is associated with ginger hair and fair skin and has been considered a risk factor for melanoma (skin cancer). Now, a new study hypothesizes that this gene also may increase the risk of Parkinson’s disease by affecting dopamine production. The study “The Melanoma-Linked “Redhead” MC1R Influences…

NeuroDerm’s Phase 2 Parkinson’s disease (PD) trial of ND0612H — a continuous infusion of levodopa and carbidopa delivered by a small belt pump — has met both primary and key secondary endpoints by demonstrating that the treatment effectively reduced “off-time” and increased the number of patients with advanced…